NCT00723710已完成不适用
Guidelines to the Intron A® Health Management Program II: A Nursing Support Program for Patients With High-Risk Melanoma Receiving High Dose Intron A Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 299
- 主要终点
- Number of Participants Who Completed Treatment
研究概览
简要总结
Patients with malignant melanoma who had undergone surgery will receive adjuvant treatment with high-dose Intron A for one year. The objective of this study is to maximize treatment compliance by proactive management of side effects in a day-to-day healthcare setting.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Age > 18 years
- •Confirmed melanoma
- •Patient has been prescribed Intron A therapy for High-Risk Stage II & III Melanoma
- •Intron A therapy started within 70 days of surgery (additional 15 days may be granted by the sponsor upon written approval)
- •Proper contraception in both male and female subjects and the female partner(s) of male study subjects
排除标准
- •Metastatic disease at the time of diagnosis
- •Other malignancies
- •History of non compliance to other therapies
- •Pregnancy or breast feeding
- •Previous Intron A therapy
结局指标
主要结局
Number of Participants Who Completed Treatment
时间窗: Up to 1 year
Treatment completion was defined as those who completed both the induction and maintenance phases.
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
2 期
Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV MelanomaMelanomaNCT02656706Brown University22
已完成
2 期
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal SequenceNeoplasm MetastasisMelanomaNCT00001705National Cancer Institute (NCI)141
招募中
不适用
Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected MelanomaMelanomaNCT05527795Hospices Civils de Lyon1,000
已完成
不适用
A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been RemovedMelanomaNCT03771859Bristol-Myers Squibb152
已完成
2 期
Trial of ABI-007 in Previously Treated Patients With Metastatic MelanomaMetastasesMelanomaNCT00093119Celgene75